Digitala Vetenskapliga Arkivet

Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Prophylactic Aspirin Dose and Preeclampsia
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Disciplinary Domain of Medicine and Pharmacy, research centers etc., Center for Clinical Research Dalarna. Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Obstet & Gynecol, Diagnosvagen 15, S-41650 Gothenburg, Sweden.ORCID iD: 0000-0001-8874-8205
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Clinical Obstetrics. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Disciplinary Domain of Medicine and Pharmacy, research centers etc., Center for Clinical Research Dalarna.ORCID iD: 0000-0001-9173-2909
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Clinical Obstetrics. Univ Iceland, Fac Med, Reykjavik, Iceland.;Landspitali Natl Univ Hosp Iceland, Dept Obstet & Gynecol, Reykjavik, Iceland..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Clinical Obstetrics.ORCID iD: 0000-0001-6431-3303
Show others and affiliations
2025 (English)In: JAMA Network Open, E-ISSN 2574-3805, Vol. 8, no 2, article id e2457828Article in journal (Refereed) Published
Abstract [en]

Importance It is unclear whether a higher dose (150-160 mg) or a lower dose (75 mg) of aspirin should be used to prevent preeclampsia. Objectives To compare the risk of preeclampsia and bleeding complications between women using 150 to 160 mg of aspirin and those using 75 mg of aspirin for preeclampsia prevention. Design, Setting, and ParticipantsThis nationwide cohort study included 13 828 women giving birth at 22 weeks' gestation or later in Sweden between January 2017 and December 2020 who used low dose aspirin (75-160 mg) during pregnancy. Data were analyzed from October to November 2023. Exposure The use of 150 to 160 mg or 75 mg of aspirin in pregnancy. Main Outcome and MeasuresThe main outcome was a preeclampsia diagnosis recorded in the maternal birth record at the time of hospital discharge. The main safety outcome was postpartum hemorrhage, defined as bleeding more than 1000 mL after delivery. Relative risks (RRs) and 95% CIs were estimated using a doubly robust inverse probability-weighted regression adjustment model controlling for background characteristics. Results In the total cohort of 13 828 women, the mean (SD) age was 33.0 (5.5) years and 3003 women (21.7%) were nulliparous. Of the women, 4687 (33.9%) were prescribed 150 to 160 mg of aspirin, and 9141 (66.1%) were prescribed 75 mg of aspirin. A total of 10 635 women (76.9%) had at least 2 dispensed prescriptions of low-dose aspirin. Among women using 150 to 160 mg of aspirin, 443 (9.5%) developed preeclampsia compared with 812 (8.9%) of those using 75 mg of aspirin (adjusted RR [aRR], 1.07; 95% CI, 0.93-1.24). Additionally, the risk of postpartum hemorrhage between the groups was similar, with 326 women (6.9%) using 150 to 160 mg of aspirin experiencing a postpartum hemorrhage compared with 581 (6.4%) in the 75-mg group (aRR, 1.08; 95% CI, 0.90-1.30). Conclusions and Relevance In this cohort study of 13 828 women, no difference was found in preeclampsia incidence or bleeding complications between those using 150 to 160 mg of aspirin vs 75 mg of aspirin during pregnancy for preeclampsia prevention. These findings suggest that either dose may be a reasonable choice when using aspirin to prevent preeclampsia. However, large randomized trials investigating aspirin dose in pregnancy are still needed.

Place, publisher, year, edition, pages
American Medical Association (AMA), 2025. Vol. 8, no 2, article id e2457828
National Category
Gynaecology, Obstetrics and Reproductive Medicine
Identifiers
URN: urn:nbn:se:uu:diva-551467DOI: 10.1001/jamanetworkopen.2024.57828ISI: 001416055100004PubMedID: 39899294Scopus ID: 2-s2.0-85217880830OAI: oai:DiVA.org:uu-551467DiVA, id: diva2:1940882
Funder
Swedish Research Council, 2020-01481Available from: 2025-02-27 Created: 2025-02-27 Last updated: 2025-02-27Bibliographically approved

Open Access in DiVA

fulltext(828 kB)39 downloads
File information
File name FULLTEXT01.pdfFile size 828 kBChecksum SHA-512
9b0e3c9062f1cb742a65459d49049dc78da673293b76966398374f1a92c42eb947638abdbb1a3e37234a0992f1ba07d9068834503912ad719d8e718a155d2371
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Kupka, EllenHesselman, SusanneGunnarsdóttir, JóhannaWikström, Anna-KarinHastie, RoxanneBergman, Lina
By organisation
Center for Clinical Research DalarnaClinical Obstetrics
In the same journal
JAMA Network Open
Gynaecology, Obstetrics and Reproductive Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 39 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 192 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf